AstraZeneca Boosts Weight Management Portfolio via CSPC Collaboration
Under this agreement, Astrazeneca and CSPC Pharmaceuticals will initially progress four programmes, which utilise CSPC's advanced Artificial Intelligence (AI)-driven peptide drug discovery platform and their proprietary LiquidGel once-monthly dosing platform technology.
Pharma Deal | 31/01/2026 | By News Bureau
Concerto and Sacco System Sign Microbial Discovery Deal
Concerto and Sacco System aim to develop novel ingredients composed of synergistically interacting microbes with desirable functional properties.
Pharma Deal | 30/01/2026 | By News Bureau
Boehringer and Simcere Partner on Dual-Target IBD Antibody
Boehringer Ingelheim has signed a licence and collaboration deal with Simcere to develop a novel TL1A/IL23p19 bispecific antibody for inflammatory bowel disease, gaining global rights outside greater China, with Simcere eligible for up to €1.058 billion in payments.
Pharma Deal | 29/01/2026 | By News Bureau
Worldwide Clinical Trials to Acquire Catalyst Clinical Research
Worldwide Clinical Trials has entered into a definitive agreement to acquire Catalyst Clinical Research, a move aimed at expanding its functional service provider capabilities, strengthening its global site network, boosting oncology expertise, and accelerating technology integration to enhance efficiency and transparency for customers.
Pharma Deal | 21/01/2026 | By News Bureau | 163
Serum Institute to Produce 100,000 Doses of Oxford Rift Valley Fever Vaccine
Serum Institute of India will produce up to 100,000 doses of an investigational Rift Valley fever vaccine developed by the University of Oxford, as the viral disease continues to affect parts of West Africa. The doses may be used for testing and future outbreak response, under an agreement supported by CEPI.
Pharma Deal | 17/01/2026 | By News Bureau
Biocon Raises INR 4,150 Crore via QIP
Biocon has successfully raised INR 4,150 crore through a Qualified Institutions Placement (QIP), with the proceeds set to be primarily used to fund the cash consideration payable to Mylan Inc. (Viatris) for the buyout of its stake in Biocon Biologics, including the repayment of related acquisition debt.
Pharma Deal | 15/01/2026 | By News Bureau
Bayer to Enter Molecular Imaging, Acquires Pan-Amyloid Radiotracers from Attralus
By acquiring AT-01 and AT-05 from Attralus, Bayer strengthens its molecular imaging and cardiovascular precision medicine portfolio, targeting earlier and more accurate diagnosis of amyloidosis.
Pharma Deal | 14/01/2026 | By News Bureau
Esco Aster Signs cGMP Exosome Manufacturing Deal with Shine-On Biomedical
Esco Aster has entered into a clinical cGMP manufacturing agreement with Shine-On Biomedical to support the production of a first-in-class HLA-G–targeting exosome drug delivery platform, while also providing technical services for exploratory exosome loading feasibility studies to advance the programme’s development.
Pharma Deal | 07/01/2026 | By News Bureau
Aurobindo Pharma Extends Timeline for Acquisition of Stake in Swarnaakshu Solar Power
Aurobindo Pharma has announced that the completion of its captive solar power purchase agreement and the acquisition of up to a 26 percent stake in Swarnaakshu Solar Power has been deferred to March 31, 2026, due to pending state government approvals for setting up the solar power plant.
Pharma Deal | 30/12/2025 | By News Bureau
Exyte Completes Pharmaplan's Integration
The completed integration of Pharmaplan marks a major milestone in Exyte’s strategy to build a leading European player in life sciences engineering and strengthen collaboration with the region’s biotechnology and pharmaceutical industries.
Pharma Deal | 28/11/2025 | By Dineshwori | 110
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy